A sulfamato hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a process for preparing the same, intermediate compounds useful in those syntheses, and a treatment process that comprises administering a contemplated sulfamato hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.
本发明公开了一种磺酰
氨基羟
肟酸化合物,该化合物在抑制基质
金属
蛋白酶活性方面具有作用,同时还公开了制备该化合物的方法,用于该合成的中间化合物以及治疗过程,该治疗过程包括向具有与病理基质
金属
蛋白酶活性相关的病情的宿主中以
MMP酶抑制有效量的考虑中的磺酰
氨基羟
肟酸化合物的方式进行给药。